Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary

Baricitinib is considered a first-line treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected adult patients with an associated cytokine storm syndrome (CSS). Our objective was to compare rates of secondary infections and long-term outcomes of elderly and non-elderly pat...

Full description

Saved in:
Bibliographic Details
Published in:GeroScience 2024-06, Vol.46 (3), p.2863-2877
Main Authors: Gáspár, Zsófia, Szabó, Bálint Gergely, Andrikovics, Hajnalka, Ceglédi, Andrea, RAJMON, Martin, Ábrahám, Anita, Várnai, Zsuzsanna, Kiss-Dala, Noémi, Szlávik, János, Sinkó, János, Vályi-Nagy, István, Lakatos, Botond
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Cell Biology
Coronaviruses
COVID-19
Cytokine storm
Geriatrics/Gerontology
Immunomodulation
Infections
Life Sciences
Molecular Medicine
Mortality
Original Article
Patients
Secondary infection
Severe acute respiratory syndrome coronavirus 2
Survival analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Baricitinib is considered a first-line treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected adult patients with an associated cytokine storm syndrome (CSS). Our objective was to compare rates of secondary infections and long-term outcomes of elderly and non-elderly patients who received baricitinib for COVID-19. We conducted a single-centre observational study between November 2020 and September 2023, focusing on hospitalized adult SARS-CoV-2 patients with CSS, categorized as elderly (≥ 65 years) and non-elderly (
ISSN:2509-2723
2509-2715
2509-2723
DOI:10.1007/s11357-024-01099-y